Margin Recovery On Watch: Can Rossari Sustain Growth While Lifting EBITDA?
Rossari opens Q2 with record Q1 revenue of ₹697 Cr (28% growth), but EBITDA margin compression to 11.6% is the elephant in the room. Street's 47% upside bet hinges on management's path back to 14-15% margins—watch for guidance clarity on ethylene oxide availability and capacity ramp.
The Setup: Growth Runs Into Margin Walls
Rossari has a classic growth vs. profitability story playing out. Q1 FY27 delivered stellar ₹697.2 Cr revenue (28% YoY)—the highest in the company's history—but EBITDA margin compressed 90 basis points to 11.6%, and PAT grew just 4.5%. The culprits: ethylene oxide (EO) supply constraints, raw material volatility, and pricing pass-through delays. Management guided FY27 at 15% revenue growth (conservative given the 28% Q1), and targets a steady-state 14–15% EBITDA margin over the next two years. Q2 will show whether management can keep the revenue momentum rolling while starting the long climb back to profitability.
~₹680–720 Cr
Tracking 15% FY27 guidance; prior Q1 ₹697 Cr was 28% YoY
11–12%
Q1 was 11.6%, down 90bps; watch for early signs of recovery
5–5.5%
Q1 at 5.0%; leverage and tax will dictate flow-through
₹160–180 Cr range
Q1 export ₹160 Cr (23–26% of total), up 21% YoY
A strong print for Q2: Revenue ₹710+ Cr with EBITDA margin holding at 11.5%+ and clear commentary that EO availability is improving on schedule (enabling volume ramp from December). Pharma business tracking ₹30–50 Cr FY27 guidance. Export momentum sustained. A weak print: Revenue below ₹670 Cr, margin slipping below 11%, or any signal that EO shortage lingers longer than December, or Pharma ramp delays. Guidance revision downward on FY27 growth would be a major red flag.
On Track? The FY27 Trajectory
Rossari is running ahead on volume (28% Q1 growth vs. 15% FY27 guide), but behind on margin. Capacity utilization is the pivot: the company is building out new facilities (Thailand blending plant at 5000 MTPA), and mix improvement is expected as it exits loss-making B2C cleaning businesses. The margin recovery thesis rests on three legs: (1) EO availability improvement post-December 2026, enabling higher-margin EO products; (2) product mix shift towards higher-margin specialties and pharma; (3) cost inflation normalization. Management has been conservative—guided only 15% despite strong Q1—so the bar for a beat is high, but execution on margin is now the real test.
Since Last Quarter: The Filings Scan
1 · Bulk buy signal (Jun–Oct): BHUPESH KUMAR LODHA purchased ₹2.98 Cr @ ₹491.50
Name scan flags this as a promoter-linked buyer. Accumulation during a period of FII/DII selling (FII down 146 bps to 2.02%, DII down 356 bps to 14.64% since Q1) is a contrarian signal worth noting—insider conviction in the margin recovery thesis, or defensive buying?
2 · Thailand facility live (Jun 26, 2026)
Rossari subsidiary Unistar Thai Co. commissioned a 5000 MTPA blending facility. This diversifies geography and margin structure away from EO-heavy India ops—a positive for medium-term resilience, though near-term impact is minimal.
3 · Trading window closed (Sep 25, 2026)
Standard pre-result blackout for insiders. No material corporate action or regulatory flag.
4 · ESOP grant (Jul 18–20, 2026): 4,000 options granted
Routine retention/incentive grant under ESOP 2019. No material dilution; corrected from initial 4,000→5,000 restatement. Suggests management confidence in execution ahead.
Rossari enters Q2 riding high on volume (₹697 Cr, 28% growth) but under pressure on margin (11.6%, compressed 90 bps). Management's bet is simple: EO supply improves from December, Pharma ramps, and cost-saving from exiting B2C drags lift EBITDA margin back to 14–15% over two years. The Street has priced 47% upside on this execution. Q2 results will be read for three things: (1) Can revenue hold above ₹680 Cr while guidance remains 15% FY27?; (2) Any early sign of margin stabilization, or does the margin squeeze continue?; (3) Confidence and timing on EO and Pharma ramp. Thin margin swings and commodity cost leverage make this quarter a litmus test for investor patience.